| 1. |
|
|
| 2. |
- Egevad, Lars, et al.
(författare)
-
Primary seminal vesicle carcinoma detected at transurethral resection of prostate
- 2007
-
Ingår i: Urology. - : Elsevier BV. - 1527-9995 .- 0090-4295. ; 69:4
-
Tidskriftsartikel (refereegranskat)abstract
- We present a case of primary seminal vesicle carcinoma detected at transurethral resection. The clinical presentation, radiologic findings, and pathologic features of these tumors are reviewed. Grossly, seminal vesicle carcinoma is poorly circumscribed and solid or solid/cystic and may be misinterpreted as an abscess or hemorrhage on radiologic examination. Although a definitive diagnosis often cannot be given until after complete resection, we describe the findings indicative of seminal vesicle origin, including papillary histologic architecture, sometimes with mucinous differentiation, and a characteristic immunophenotype positive for CA-125 and cytokeratin 7, but negative for prostate-specific antigen and cytokeratin 20. UROLOGY 69: 778.e11-78.e13, 2007.
|
|
| 3. |
|
|
| 4. |
|
|
| 5. |
- Ranti, Daniel, et al.
(författare)
-
Surveillance for Nonmuscle Invasive Bladder Cancer: Identifying the Point of Diminishing Returns
- 2023
-
Ingår i: UROLOGY. - 0090-4295 .- 1527-9995. ; 181, s. 84-91
-
Tidskriftsartikel (refereegranskat)abstract
- OBJECTIVE To characterize first and second recurrence patterns using 26 years of cohort-level follow-up and microsimulation modeling.METHODS Patients diagnosed with nonmuscle-invasive bladder cancer in Stockholm County between 1995 and 1996 were included. Clinical, pathological, and longitudinal follow-up data were gathered. Logistic regressions, Kaplan Meier curves, and Cox proportional hazards models were run to generate assumptions for a microsimulation model, simulating first and second recurrence and progression for 10,000 patients.RESULTS Three hundred eighty-six patients were included: 67.4% were male; > 50% were TaLG; and 37.5% were American Urological Association high-risk. Median time to recurrence was 300 days. Three patients had missing data. Cohort follow-up has been carried out for 26 years. For simulated firstrecurrences, low-risk patients recurred at 56.6% over 15 years of follow-up, with 2.2% muscleinvasive (MI) progression; intermediate-risk patients recurred at 62.8%, with 4.3% MI progression; high-risk patients recurred at 48.7% over 15 years, with MI progression at 14.3%. For second recurrences, 70.7%, 75.7%, and 84.7% of low, medium, and high-risk patients recurred. No patients were seen to have first recurrences after 9 years, with low, but notable, rates beyond 5 years.CONCLUSION These data suggest that low-, intermediate-, and high-risk patients without recurrence at 5 years may be potentially transitioned to less invasive monitoring.
|
|
